AstraZeneca PLC (LON:AZN) Given Consensus Rating of "Moderate Buy" by Brokerages
AstraZeneca PLC (LON:AZN) has received a consensus "Moderate Buy" rating from six brokerages, with one analyst issuing a sell rating and five a buy rating. The average one-year price target is £145.83. Recent analyst coverage includes upgrades to price targets and reiterated buy ratings, alongside one new "sell" rating and one new "buy" rating with a £170 price target.
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Assembly Biosciences (NASDAQ: ASMB) has received a "Moderate Buy" consensus recommendation from seven research firms, with an average 12-month target price of $41.75. The biopharmaceutical company, focused on hepatitis B and D therapies, saw its shares open up 10.7% at $28.75. Institutional investors have significantly increased their stakes in the company, with hedge funds owning 19.92% of the stock.
697,395 Shares in Duke Energy Corporation $DUK Purchased by ANTIPODES PARTNERS Ltd
ANTIPODES PARTNERS Ltd acquired 697,395 shares of Duke Energy (NYSE:DUK) valued at approximately $86.31 million in the third quarter, making it their 22nd largest position. Duke Energy recently exceeded Q4 earnings estimates with an EPS of $1.50 and revenue of $7.94 billion, and declared a quarterly dividend of $1.065. The stock holds a "Moderate Buy" consensus rating with a target price of $135.75, though analysts' views are mixed due to regulatory issues and customer bill spikes alongside positive developments like a strong nuclear reliability record.
AMG National Trust Bank Acquires 45,996 Shares of Merck & Co., Inc. $MRK
AMG National Trust Bank significantly increased its stake in Merck & Co., Inc. by 151.9%, acquiring an additional 45,996 shares, bringing their total holdings to 76,273 shares valued at approximately $6.402 million. This increase occurred amidst recent insider selling activities where executives sold shares worth over $43 million combined. Analysts maintain a "Moderate Buy" rating for Merck, with an average price target of $124.80.
ANTIPODES PARTNERS Ltd Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY
ANTIPODES PARTNERS Ltd significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 74% in Q3, selling 90,848 shares,
AMG National Trust Bank Invests $3.71 Million in IQVIA Holdings Inc. $IQV
AMG National Trust Bank has initiated a new position in IQVIA Holdings Inc. by purchasing $3.71 million worth of shares. Other institutional investors like AllianceBernstein, Artisan Partners, JPMorgan, Nordea, and Cantillon Capital Management have also adjusted their holdings in IQVIA. Despite analysts trimming price targets, IQVIA holds a "Moderate Buy" consensus rating with an average target of $235.20 and recently exceeded EPS estimates while providing strong FY2026 guidance.
ANTIPODES PARTNERS Ltd Sells 435,646 Shares of Ventas, Inc. $VTR
ANTIPODES PARTNERS Ltd has reduced its stake in Ventas, Inc. (NYSE:VTR) by 28.4%, selling 435,646 shares. Despite the sell-off, Ventas remains the fund's 26th largest holding, and analysts maintain a "Moderate Buy" rating for the stock with an average price target of $86.87. The company recently missed quarterly EPS and revenue estimates but raised its quarterly dividend to $0.52 and set optimistic FY2026 guidance.
Annis Gardner Whiting Capital Advisors LLC Purchases 22,940 Shares of NVIDIA Corporation $NVDA
Annis Gardner Whiting Capital Advisors LLC increased its stake in NVIDIA Corporation (NVDA) by 49.5%, acquiring an additional 22,940 shares, bringing its total to 69,267 shares valued at $12.924 million. This makes NVIDIA its 5th largest holding, accounting for 2.7% of its portfolio. The move comes as NVIDIA continues to report strong earnings, with Q3 EPS beating estimates and revenue up 62.5% year-over-year, supported by strategic partnerships and ongoing demand from the AI sector, despite some analyst concerns about high pricing and potential post-earnings pullbacks.
Super Micro Computer: The Less Discussed FQ2 Accounting Items (NASDAQ:SMCI)
Super Micro Computer (SMCI) receives an upgrade to Buy following a recent selloff, with the article highlighting that investment expenses and other near-term negatives are now priced in. The company's FQ2 2026 cash flow reconciliation reveals significant investments, anticipating future cash flow boosts from changes in accounts receivable and inventory. SMCI is considered to have compelling valuation at a forward P/E of approximately 14.4x, supported by strong consensus EPS growth predictions for 2026 and 2027, despite potential risks from margin pressure and customer concentration.
Vistra Corp.: Can This Quiet Power Play Still Shock the Market?
Vistra Corp. has transitioned from a Texas power producer to a closely watched utility stock on Wall Street, benefiting from AI-driven electricity demand and clean energy build-out. While analysts are largely positive, recognizing its outperformance and capital returns, the article questions if the stock still offers significant upside for investors given its massive run. Investors are advised to consider its sensitivity to ERCOT dynamics, natural gas prices, and interest rates, and to thoroughly evaluate risks before investing.
Tractor Supply (NASDAQ:TSCO) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Tractor Supply (NASDAQ:TSCO) from a "hold" to a "sell" rating. This decision comes despite a consensus "Moderate Buy" rating from fifteen analysts, with a target price of $59.78. The company recently missed earnings estimates, and several insiders have sold shares, though institutional ownership remains high at 98.72%.
ANTIPODES PARTNERS Ltd Invests $68.20 Million in American Tower Corporation $AMT
ANTIPODES PARTNERS Ltd has initiated a new position in American Tower Corporation (NYSE:AMT), purchasing 354,584 shares valued at approximately $68.20 million. This investment represents about 1.5% of Antipodes' portfolio and roughly 0.08% of American Tower's outstanding shares. Other institutional investors like Vanguard Group and JPMorgan Chase & Co. have also adjusted their holdings in the real estate investment trust, which maintains an average analyst rating of "Moderate Buy" and offers a 3.6% dividend yield.
958,355 Shares in Evergy Inc. $EVRG Bought by ANTIPODES PARTNERS Ltd
ANTIPODES PARTNERS Ltd acquired a new stake of 958,355 shares in Evergy Inc. (NASDAQ:EVRG) during Q3, valued at approximately $72.86 million, representing 1.6% of the fund's portfolio. Despite a Q4 EPS miss and slightly lower FY-2026 guidance, Evergy announced a quarterly dividend of $0.695 per share, offering a 3.5% yield. Several Wall Street analysts have recently reiterated or increased their price targets for Evergy.
Advyzon Investment Management LLC Trims Position in BondBloxx Bloomberg Three Year Target Duration US Treasury ETF $XTRE
Advyzon Investment Management LLC has reduced its stake in the BondBloxx Bloomberg Three Year Target Duration US Treasury ETF (XTRE) by 27.0% in the third quarter, now owning 60,309 shares valued at $3.006 million. Several other institutional investors also adjusted their positions in XTRE, with some increasing their holdings and others initiating new stakes. The ETF recently declared a monthly dividend of $0.1695 per share, representing an annualized yield of 4.1%.
Aberdeen Group plc Reduces Holdings in Builders FirstSource, Inc. $BLDR
Aberdeen Group plc has decreased its stake in Builders FirstSource (NYSE:BLDR) by 18.1%, selling 15,205 shares and now owning 69,030 shares valued at $8.26 million. Builders FirstSource missed its Q4 earnings and revenue estimates, reporting EPS of $1.12 against an expected $1.30 and revenue of $3.36 billion against $3.46 billion, marking a 12.1% year-over-year decline. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $129.02, while the stock recently traded around $110.38 against a 52-week range of $94.35–$151.03.
Aberdeen Group plc Has $6.89 Million Stake in NVR, Inc. $NVR
Aberdeen Group plc increased its stake in NVR, Inc. to 851 shares, valued at approximately $6.89 million, representing a 25% increase in Q3. NVR reported strong Q4 earnings, beating analyst expectations with an EPS of $121.54 and revenue of $2.74 billion, despite a 5.2% year-over-year revenue decrease. The company also announced a $750 million share repurchase program, while insiders sold shares totaling about $9.01 million.
Aberdeen Group plc Invests $7.04 Million in XPLR Infrastructure, LP $XIFR
Aberdeen Group plc has purchased a new stake worth approximately $7.04 million in XPLR Infrastructure, LP (NYSE:XIFR), a solar energy provider. This investment represents 0.73% of XPLR Infrastructure, and other institutional investors have also adjusted their holdings. The company's stock performances, financial ratios, recent earnings, and analyst ratings are also provided, with a consensus "Reduce" rating and a target price of $12.58.
625,000 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by Aberdeen Group plc
Aberdeen Group plc recently acquired 625,000 shares of Aquestive Therapeutics (NASDAQ:AQST), valued at over $3.49 million, representing a 0.63% stake in the company. Several other institutional investors also increased their positions in AQST, with hedge funds and institutions now owning approximately 32.45% of the stock. Despite a consensus "Buy" rating and an $8.50 price target from analysts, AQST's stock trades around $3.95, below its 50-day and 200-day moving averages.
Aberdeen Group plc Sells 26,708 Shares of United Airlines Holdings Inc $UAL
Aberdeen Group plc reduced its stake in United Airlines Holdings Inc (UAL) by 26.5%, selling 26,708 shares and now holding 74,234 shares valued at $7.16 million. This follows significant insider sales by CEO J. Scott Kirby and President Brett J. Hart. Despite these sales, United Airlines beat quarterly EPS estimates, provided strong FY-2026 EPS guidance, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $137.32.
Advyzon Investment Management LLC Boosts Holdings in ProShares UltraPro QQQ $TQQQ
Advyzon Investment Management LLC significantly increased its stake in ProShares UltraPro QQQ (TQQQ) by 145.6% in Q3, holding 45,678 shares valued at $4.723 million. This surge reflects a broader institutional accumulation, with other major firms like Howard Capital, Citigroup, and Goldman Sachs also substantially boosting their TQQQ holdings. Additionally, ProShares UltraPro QQQ recently increased its quarterly dividend to $0.0855 per share, up from $0.05.
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX
Aberdeen Group plc significantly increased its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 22.9% in the third quarter, bringing their total holdings to 372,792 shares valued at $5.735 million. This increase makes Aberdeen Group plc the largest institutional shareholder in the company. Despite insider selling by the CEO and CFO in February 2026, analysts maintain a "Moderate Buy" consensus rating with an average target price of $37.20.
Aberdeen Group plc Sells 39,392 Shares of Sociedad Quimica y Minera S.A. $SQM
Aberdeen Group plc reduced its stake in Sociedad Quimica y Minera S.A. (NYSE:SQM) by 17.9% in the third quarter, selling 39,392 shares and holding 180,758 shares valued at $7.74 million. Other institutional investors like Royal Bank of Canada and Goldman Sachs Group Inc. increased their holdings in SQM. The stock currently has a "Moderate Buy" rating from analysts with an average target price of $69.79.
Anthropic's new tool wipes down billions from CrowdStrike, Cloudflare, Palo Alto Networks, and Zscaler, Okta stocks; company says: We also... - The Times of India
Anthropic introduced Claude Code Security, an AI-powered tool for scanning codebases for vulnerabilities, causing a significant sell-off in cybersecurity stocks. Major companies like CrowdStrike, Cloudflare, Okta, SailPoint, Zscaler, Palo Alto Networks, and Fortinet saw their shares drop by 2-9%. This disruption is attributed to fears that AI could significantly alter the cybersecurity landscape, despite some analysts believing AI will ultimately benefit the sector.
Aberdeen Group plc Trims Position in Tenet Healthcare Corporation $THC
Aberdeen Group plc significantly reduced its stake in Tenet Healthcare Corporation (NYSE:THC) by 37.5% in the third quarter, selling 22,372 shares. Despite this reduction, analysts maintain a broadly bullish outlook, with a consensus "Moderate Buy" rating and a target price of $247.67. Tenet Healthcare recently surpassed quarterly earnings estimates, reporting $4.70 EPS and $5.53 billion in revenue, and set strong FY2026 guidance.
NVIDIA Corporation $NVDA is Activest Wealth Management's 7th Largest Position
Activest Wealth Management increased its stake in NVIDIA (NVDA) by 11.1% in Q3, making it their 7th largest holding at $13.9 million. NVIDIA reported strong Q4 earnings, beating analyst estimates with significant revenue growth. The company benefits from an expanded Meta partnership and a potential investment in OpenAI, though risks include a possible post-earnings pullback and emerging competition from ASIC manufacturers.
Nvidia and Broadcom Compete in AI Infrastructure
Nvidia dominates the GPU market for AI workloads, holding over 90% market share, while Broadcom leads in custom ASIC technology, offering energy-efficient alternatives. Broadcom's strategic partnerships with Alphabet for Tensor Processing Units (TPUs) and a $21 billion order from Anthropic position it for significant growth in the competitive AI infrastructure space. Despite Nvidia's current lead, Broadcom's specialization in custom chips and data center networking makes it a strong contender for future AI buildouts.
Transformasi TLKM 3.0 Picu Lonjakan Saham Telkom Hingga 30 Persen
Saham PT Telkom Indonesia (TLKM) mengalami kenaikan signifikan sebesar 30.34% dalam setahun terakhir, mencapai 3,480 per saham. Kenaikan ini didorong oleh kepercayaan investor terhadap perusahaan dan agenda transformasi TLKM 3.0. Inisiatif strategis ini bertujuan menjadikan Telkom Group lebih agile, kompetitif, dan meningkatkan valuasi perusahaan melalui operational excellence dan restrukturisasi.
Uber Technologies Stock To $96?
Trefis has a positive outlook on Uber Technologies (UBER) stock, suggesting it's an attractive buy with a potential to reach $96. This assessment is based on Uber's strong operating performance, financial condition, very strong growth, and moderate valuation, despite its very weak downturn resilience. The analysis details UBER's valuation, growth, profitability, and financial stability compared to the broader market.
Taiwan Semiconductor Set to Benefit from Surge in AI Spending
Taiwan Semiconductor (TSM) is expected to significantly benefit from the surge in AI spending, with major AI hyperscalers projected to spend around $650 billion on data center capital expenditures by 2026. TSM is considered uniquely positioned in the AI chip market, serving clients like Nvidia and AMD, and anticipates a nearly 60% compound annual growth rate in AI chip revenue from 2024 to 2029. Despite this strong growth outlook, the company's stock currently trades at a reasonable price-to-earnings ratio of 26, slightly above the S&P 500's 22, making it an attractive investment in the AI buildout.
Nordson (NASDAQ:NDSN) Raised to Buy at Wall Street Zen
Wall Street Zen has upgraded Nordson (NASDAQ:NDSN) from a "hold" to a "buy" rating, though the collective analyst consensus remains a "Hold" with a target price of $276.14. Nordson reported a strong Q1 with record revenue and in-line EPS, and raised its FY2026 guidance, supporting a positive forward earnings outlook. Despite strong top-line results, factors like mixed EPS readings, insider selling, and recent fund adjustments could introduce selling pressure.
Trinity Industries (NYSE:TRN) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Trinity Industries (NYSE:TRN) from a "hold" to a "buy" rating. This upgrade comes as the company continues to generate interest from other analysts, with a consensus "Hold" rating and an average target price of $33.50 among other institutions. Trinity Industries recently reported strong quarterly earnings, surpassing analyst expectations with $2.31 EPS and $611.20 million in revenue.
Q2 (NYSE:QTWO) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen upgraded Q2 (NYSE:QTWO) from a "buy" to a "strong-buy" rating, indicating increased analyst confidence. Other firms like DA Davidson and Morgan Stanley have also issued "buy" ratings and price targets for Q2, despite recent insider share sales. The company, which provides cloud-based digital banking solutions, maintains a "Moderate Buy" average rating from analysts with an average price target of $79.29.
Southern Copper (NYSE:SCCO) Upgraded to Buy at Wall Street Zen
Southern Copper (NYSE:SCCO) has been upgraded to a "buy" rating by Wall Street Zen. This upgrade comes amidst mixed ratings from other analysts, with a consensus "Reduce" rating and an average target price of $136.49 for the stock. The article also details recent insider selling activities and institutional trading in Southern Copper shares.
Oceaneering International (NYSE:OII) Stock Rating Upgraded by Wall Street Zen
Oceaneering International (NYSE:OII) had its stock rating upgraded by Wall Street Zen from "hold" to "buy." Despite this upgrade and a slight Q4 EPS beat, the consensus rating from MarketBeat remains "Hold" with an average target price of $25. The company expects multi-year growth from ADTech and guided for $390M–$440M EBITDA in 2026, though recent insider selling and conservative analyst targets temper near-term upside.
Federal Agricultural Mortgage (NYSE:AGM) Cut to Sell at Wall Street Zen
Wall Street Zen downgraded Federal Agricultural Mortgage (AGM) to a "sell" rating following a significant miss on quarterly earnings and revenue, causing the stock to fall by about 14%. Despite this, the broader MarketBeat consensus for AGM remains a "Moderate Buy" with a $219 target price, indicating a divergence among analysts regarding the company's future outlook. Federal Agricultural Mortgage, also known as Farmer Mac, is a government-sponsored enterprise providing liquidity and risk management for agricultural and rural utility loans.
Smith & Nephew SNATS (NYSE:SNN) Lowered to Buy Rating by Wall Street Zen
Wall Street Zen has downgraded Smith & Nephew SNATS (NYSE:SNN) from a "strong-buy" to a "buy" rating. Despite this, other firms have weighed in with varying ratings, and the consensus among analysts is a "Hold" with a price target of $35.75. The company's stock is currently trading at $36.10, showing institutional investor interest while analysts recommend holding rather than buying Smith & Nephew SNATS.
Medtronic (NYSE:MDT) Rating Increased to Buy at Wall Street Zen
Wall Street Zen upgraded Medtronic (NYSE:MDT) to a "buy" rating, reflecting a "Moderate Buy" consensus among analysts with an average target price of $111.05. This upgrade follows Medtronic's slight beat on Q3 earnings and revenue estimates, alongside strong institutional buying, including a significant new position from Norges Bank. The article also details recent analyst actions, financial performance metrics, and various market sentiments impacting the company.
Service Corporation International (NYSE:SCI) Downgraded by Wall Street Zen to Sell
Equities researchers at Wall Street Zen downgraded Service Corporation International (NYSE:SCI) from a "hold" rating to a "sell" rating. This comes despite other analysts maintaining or upgrading their ratings, with the company currently holding an average "Buy" rating and a consensus target price of $96.50. The article also provides financial performance data, insider activity, and institutional investor movements for SCI.
Arcosa (NYSE:ACA) Raised to "Buy" at Wall Street Zen
Wall Street Zen has upgraded Arcosa (NYSE:ACA) from a "hold" to a "buy" rating, aligning with other bullish assessments from Barclays and Weiss Ratings. The stock currently holds a consensus "Moderate Buy" rating with an average price target of $117.50, significantly below its current trading price of $126.35. Institutional investors maintain a strong position in the company, owning over 90% of its stock.
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Acumen Pharmaceuticals (NASDAQ:ABOS) from a "sell" to a "hold" rating. Despite this upgrade, insider selling has been noted, with CEO Daniel O'Connell selling over 37,000 shares which reduced his stake by 5.74%. The company currently holds an average analyst rating of "Moderate Buy" with a target price of $6.80.
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages
ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received an average "Moderate Buy" rating from six brokerages, with an average one-year target price of $2.50. This consensus includes four buy ratings, one hold, and one sell recommendation. Insider activity shows Director Corey S. Goodman recently purchased over 3.1 million shares, significantly increasing his stake, and institutional investors also modified their holdings.
AAR (NYSE:AIR) Upgraded by Wall Street Zen to "Buy" Rating
Wall Street Zen has upgraded AAR (NYSE:AIR) from a "hold" to a "buy" rating, reflecting a consensus analyst rating of "Moderate Buy" with a target price of $110.80. The upgrade follows AAR's strong quarterly earnings, where it surpassed expectations with $1.18 EPS and $795.3 million in revenue, leading to its stock trading near its 52-week high. Despite significant insider selling, institutional ownership remains high at 90.74%, indicating continued investor confidence.
Wall Street Zen Downgrades Acadia Realty Trust (NYSE:AKR) to Sell
Wall Street Zen has downgraded Acadia Realty Trust (NYSE:AKR) from a "hold" to a "sell" rating following the company missing quarterly EPS expectations by $0.28, despite a 12.3% year-over-year revenue increase to $104.77 million. The real estate investment trust currently holds an average "Hold" rating from analysts with a consensus target price of $22.33, while trading near $20.27. Institutional investors have shown mixed activity, with some increasing and others initiating stakes in AKR.
Alector (NASDAQ:ALEC) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Alector (NASDAQ:ALEC) from a "sell" to a "hold" rating, contributing to a mixed analyst sentiment with a consensus "Hold" rating and an average price target of $3.25. The article highlights recent insider stock sales totaling around $220,064 and details the company's financial metrics and institutional ownership. Alector, a clinical-stage biotechnology company, focuses on developing immuno-neurology therapies for neurodegenerative disorders like Alzheimer's and frontotemporal dementia.
ZTO Express (Cayman) (NYSE:ZTO) Downgraded by Wall Street Zen to Hold
Wall Street Zen has downgraded ZTO Express (Cayman) (NYSE:ZTO) from "buy" to "hold." The company recently missed earnings expectations, reporting an EPS of $0.43 against an anticipated $2.51, although revenue increased by 11.1%. ZTO Express currently holds a "Moderate Buy" consensus rating from analysts with a target price of $22.36, while institutional investors own approximately 41.65% of the stock.
Evergy (NASDAQ:EVRG) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Evergy (NASDAQ:EVRG) from a "sell" to a "hold" rating, indicating improved sentiment even though the company's Q4 EPS missed expectations and 2026 guidance is slightly below Street consensus. Despite mixed operational results, Evergy declared a quarterly dividend and announced a substantial five-year capital expenditure plan of approximately $21.6 billion. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $85.50.
Wall Street Zen Upgrades DaVita (NYSE:DVA) to Buy
Wall Street Zen has upgraded DaVita (NYSE:DVA) from "hold" to "buy," with other firms like UBS also raising their price targets, despite MarketBeat's consensus remaining a "Hold." DaVita recently surpassed quarterly earnings and revenue estimates and provided positive FY2026 guidance. The stock is currently trading near $150.89 with a P/E of 15.23, and institutional investors and hedge funds hold a significant portion of its shares.
ConocoPhillips (NYSE:COP) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded ConocoPhillips (NYSE:COP) from a "hold" to a "sell" rating. This comes despite several other analysts maintaining "outperform" or "overweight" ratings with various price targets. ConocoPhillips recently missed analysts' consensus earnings estimates in its last quarterly report, and its CEO sold a significant number of shares in December.
Wall Street Zen Downgrades Charles River Laboratories International (NYSE:CRL) to Hold
Wall Street Zen has downgraded Charles River Laboratories International (NYSE:CRL) from a "buy" to a "hold" rating. Despite the downgrade, other analysts have set varying price targets, and the company recently reported stronger-than-expected quarterly earnings and provided its FY 2026 guidance. Institutional investors have also been actively adjusting their positions in the stock.
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Voyager Therapeutics (NASDAQ:VYGR) from a "hold" to a "sell" rating, despite a broader "Moderate Buy" consensus among analysts with an average price target of $13.75 compared to the current trading price of $3.49. Recent insider selling by CEO Alfred Sandrock contrasts with significant institutional buying, such as EcoR1 Capital increasing its stake to over 4 million shares. Voyager Therapeutics is a clinical-stage biotechnology company focusing on gene therapies for neurological diseases, utilizing proprietary platforms for AAV vector development.
